Due to the well-established role of VEGF in promoting tumor angiogenesis and the pathogenesis of human cancers, most of the angiogenesis inhibitors that are used clinically for cancer treatment target the VEGF-VEGF receptor (VEGFR) pathway2–4. The gene discussed is KDR; the disease is neoplasm.